Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) Director Sean Ellis bought 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average price of $1.23 per share, for a total transaction of $12,300.00. Following the acquisition, the director directly owned 188,098 shares of the company's stock, valued at $231,360.54. This represents a 5.61% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Sean Ellis also recently made the following trade(s):
- On Monday, February 9th, Sean Ellis purchased 18,000 shares of Entera Bio stock. The stock was bought at an average price of $1.24 per share, with a total value of $22,320.00.
Entera Bio Stock Up 6.4%
NASDAQ:ENTX opened at $1.33 on Tuesday. The firm has a market capitalization of $60.99 million, a price-to-earnings ratio of -5.32 and a beta of 1.83. Entera Bio Ltd. has a twelve month low of $1.00 and a twelve month high of $3.22. The stock's 50 day moving average price is $1.50 and its two-hundred day moving average price is $1.96.
Institutional Trading of Entera Bio
A number of hedge funds have recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC lifted its position in shares of Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company's stock valued at $1,157,000 after buying an additional 29,629 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Entera Bio during the 4th quarter worth approximately $263,000. Renaissance Technologies LLC increased its holdings in shares of Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock worth $210,000 after acquiring an additional 19,601 shares during the last quarter. Jane Street Group LLC raised its stake in Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock valued at $144,000 after acquiring an additional 43,536 shares during the period. Finally, HighTower Advisors LLC raised its stake in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after acquiring an additional 25,000 shares during the period. 14.11% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages recently weighed in on ENTX. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, February 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Entera Bio in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Entera Bio to a "sell" rating in a research report on Saturday, December 27th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $10.00.
Read Our Latest Report on Entera Bio
About Entera Bio
(
Get Free Report)
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
